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As a percutaneous technique for the reduction of mitral regurgitation, the MitraClip sys-
tem (Abbott Vascular, Abbott Park, IL, USA) for transcatheter edge-to-edge repair of the 
mitral valve was developed in 1998 and first used in 2003. Its main advantage is being 
less invasive than surgery, because it can be performed through a transcatheter approach 
without any hemodynamic compromise. Recent studies have shown that this procedure 
reduces symptoms and improves functional capacity with low complication rates. Two 
randomized clinical trials have investigated the use of this technique for functional mitral 
regurgitation. The Korean Ministry of Food and Drug Safety approved its use for degener-
ative mitral regurgitation in 2019, and this procedure started to be performed in Korea in 
January 2020. Its use for functional mitral regurgitation was also approved in Korea in 2020. 
In this article, recent evidence on transcatheter edge-to-edge repair of the mitral valve and 
our initial experiences in Korea will be reviewed.
Keywords: Mitral regurgitation, Transcatheter edge-to-edge repair, Heart valve disease, 
Mitral valve repair
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Introduction
As a percutaneous technique to reduce mitral regurgita-
tion (MR), the MitraClip system (Abbott Vascular, Abbott 
Park, IL, USA) for transcatheter edge-to-edge repair 
(TEER) of the mitral valve was developed in 1998 and first 
used in 2003. The main advantage of the TEER procedure 
that it is less invasive than surgery because it can be per-
formed via the femoral venous approach without any he-
modynamic compromise. Furthermore, unlike other per-
cutaneous cardiovascular interventions such as coronary 
or aortic valve interventions, contrast medium is not re-
quired.
Based on recent results and evidence from randomized 
clinical trials, the use of MitraClip system was permitted 
in Europe (Conformité Européene, CE Mark) in 2008. In 
the United States, the Food and Drug Administration ap-
proved it in 2013 for degenerative MR, and in 2018 for 
functional MR. The Korean Ministry of Food and Drug 
Safety approved its use for degenerative MR in 2019, and 
this procedure started to be performed in Korea in January 
2020. Its use for functional MR was also approved in Korea 
in 2020. In this article, recent evidence regarding TEER 
and our initial experiences in Korea will be reviewed.
Recent clinical trials and evidence for 
TEER
After the phase I feasibility study of the Endovascular 
Valve Edge-to-edge Repair Study (EVEREST) trial with 55 
patients [1,2], the EVEREST II trial randomized 279 pa-
tients with 3+ or 4+ MR to receive TEER with the Mitra-
Clip or open mitral valve surgery in a 2:1 ratio [3]. Patients 
with both degenerative and functional MR were enrolled, 
and functional MR was present in 27% of patients [3]. In 
the surgery group, 86% of patients were treated with mitral 
valve repair and 14% had mitral valve replacement. The 
primary endpoint, a composite of freedom from death, 
surgery for mitral valve dysfunction, and 3+ or 4+ MR at 
12 months, was achieved in 55% of patients in the percuta-
neous repair group and 73% of those in the surgical group 
(p=0.007) [3]. This difference was mainly driven by the 
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need for surgery for mitral valve dysfunction (20% in the 
percutaneous repair group versus 2% in the surgical repair 
group, p<0.001). However, major adverse events within the 
first 30 days occurred more frequently in the surgery 
group, mainly driven by the need for blood transfusions 
(13% versus 45%, p<0.001). Thus, though percutaneous re-
pair was less effective at reducing MR than surgery, TEER 
was superior in terms of safety and showed similar im-
provements in clinical outcomes [3]. According to the sec-
ondary analyses, percutaneous repair resulted in greater 
preservation of left ventricular (LV) function and a smaller 
decrease in LV dimensions compared with surgery. When 
the EVEREST II population was followed for 5 years, the 
primary endpoint still favored the surgical group (64.3% in 
the surgical group and 44.2% in the percutaneous repair 
group) [4]. However, there was no significant difference in 
the rate of death (21% versus 27%), and freedom from mi-
tral valve surgery or reoperation remained the same after 
percutaneous repair or surgery beyond 6 months after the 
procedure. Improvements in symptoms and LV dimensions 
were maintained at 5 years in both groups [4]. The EVER-
EST II trial became the landmark trial for commercial ap-
proval in the United States, particularly for degenerative 
MR.
Functional MR is frequently present in patients with ad-
vanced heart failure. Optimal medical and cardiac resyn-
chronization therapy have been proposed as first-line strat-
egies for functional MR. Surgical intervention may be 
considered in patients who are refractory to currently 
available medical or cardiac resynchronization therapy as a 
class IIb indication because the beneficial effect of mitral 
valve surgery has not been proven by prospective random-
ized clinical trials [5,6]. Meanwhile, transcatheter mitral 
intervention can be better option with a less invasive strat-
egy in high-risk population with surgery and comparable 
strategy to mitral valve surgery. In 2018, two important 
randomized trials that included the patients with function-
al MR and heart failure, the MITRA-FR (Percutaneous Re-
pair with the MitraClip Device for Severe Functional/ 
Secondary Mitral Regurgitation) trial and COAPT (Car-
diovascular Outcomes Assessment of the MitraClip Percu-
taneous Therapy for Heart Failure Patients with Function-
al Mitral Regurgitation) trial, were published [7,8]. It is 
interesting to note that these 2 trials gave different results, 
as the MITRA-FR trial failed to prove superiority for the 
primary endpoint, but the COAPT trial proved it. The MI-
TRA-FR study randomized 307 patients with symptomatic 
LV dysfunction and significant secondary MR to either 
medical therapy or medical therapy combined with the 
MitraClip procedure, and 92% of patients achieved an MR 
grade of 2+ immediately after the procedure [7]. There was 
no difference in the primary outcome of all-cause death 
and unplanned re-hospitalization for heart failure at 1 year, 
which occurred in 55% of the intervention group and 51% 
of the control group (odds ratio, 1.16; p=0.53) [7]. In the 
other COAPT trial, a total of 614 patients with symptomat-
ic heart failure and moderate-to severe or severe secondary 
MR to medical therapy or medical therapy and MitraClip 
repair [8]. The primary outcome was the rate of hospital-
ization for heart failure within 24 months, which was 
35.8% per patient-year in the device group as compared 
with 67.9% in the control group (hazard ratio, 0.53; 
p<0.001) [8]. Moreover, the powered secondary endpoint of 
death from any cause within 24 months was significantly 
lower, occurring in 29.1% of the patients in the device 
group versus 46.1% in the control group (hazard ratio, 0.62; 
p<0.001). All prespecified secondary endpoints including 
quality of life and functional assessments significantly im-
proved in the MitraClip arm [9,10].
The following reasons have been proposed for these dis-
cordant results [11-13]. First, the definitions of severe MR 
were different between European and American guide-
lines. MR was more severe in the COAPT trial than in the 
MITRA-FR trial. Second, the LV end-diastolic volumes 
were smaller in the COAPT trial than in the MITRA-FR 
trial (101 versus 135 mL/m2). Third, more aggressive guide-
line-directed medical therapy was overseen by the screen-
ing committee in the COAPT trial. Fourth, the number of 
patients receiving more than 1 clip was higher in the 
COAPT trial, possibly explaining the higher proportion of 
patients with moderate-to-severe or severe residual MR at 
1 year in the MITRA-FR trial (17% versus 5% in COAPT). 
In light of the apparently discordant results from 2 recent 
randomized controlled trials of mitral valve repair, the 
concept of the characterization of MR as proportionate or 
disproportionate to LV size was proposed to differentiate 
patients who can benefit from the TEER procedure as part 
of optimal treatment for chronic heart failure and systolic 
dysfunction [11,12]. Patients with heart failure, an LV ejec-
tion fraction (LVEF) of 30%, an LV end-diastolic volume of 
220 to 250 mL, and a regurgitation fraction of 50% would 
be expected to have an effective regurgitant orifice area of 
approximately equal to 0.3 cm2 independent of specific 
tethering abnormalities of the mitral valve leaflets [11]. The 
MR in these patients is proportionate to the degree of LV 
dilatation and can respond to drugs and devices that re-
duce LV end-diastolic volume. In contrast, patients with an 
effective regurgitant orifice area of 0.3 to 0.4 cm2, but with 
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an LV end-diastolic volume of only 160 to 200 mL, exhibit 
degrees of MR that are disproportionately higher than 
would be predicted by LV end-diastolic volume. Thus, 
these patients were proposed to preferentially benefit from 
interventions directed at the mitral valve [11-13].
Recommendations and indications for 
TEER according to current guidelines
For the assessment of the feasibility of TEER, a rigorous 
echocardiographic assessment and multidisciplinary team 
consensus is required [14]. The anatomically favorable fea-
tures of TEER are non-commissural pathology (medial, 
middle, lateral segments), no or minimal calcification, 
mean trans-mitral gradient <4 mm, mitral valve area ≥4 
cm2, and a grasping zone length >10 mm [14]. For primary 
MR, flail width <15 mm, flail gap <10 mm, single segment 
pathology, and normal leaflet thickness are also favorable 
features. For secondary MR, coaptation depth <11 mm and 
coaptation length (overlap length) ≥2 mm are favorable.
The 2020 American College of Cardiology/American 
Heart Association guideline, for the patients with primary 
MR, recommended that TEER is reasonable in severely 
symptomatic patients (New York Heart Association 
[NYHA] class III or IV) with primary severe MR and high 
or prohibitive surgical risk if the mitral valve anatomy is 
favorable for the repair procedure and the patient’s life ex-
pectancy is at least 1 year, as a class IIa recommendation 
[5]. It is notable that the previous 2017 European Society of 
Cardiology guideline recommended that TEER may be 
considered in patients with symptomatic severe primary 
MR who fulfil the echocardiographic criteria of eligibility 
and are judged inoperable or at high surgical risk by the 
heart team, avoiding futility, as a class IIb recommenda-
tion [6].
As for chronic secondary MR, TEER is reasonable (class 
IIa) in patients with appropriate anatomy as defined on 
transesophageal echocardiography and with an LVEF be-
tween 20% and 50%, LV end-systolic diameter ≤70 mm, 
and pulmonary artery systolic pressure ≤70 mm Hg, in pa-
tients with chronic severe secondary MR related to LV sys-





Fig. 1. Step-by-step procedure. (A–
C) Trans-septal pucture. Tenting of 
the atrial septum (white arrow) can 
be seen in transesophageal echocar-
diography (TEE) images of short-axis 
and 4-chamber views. (D, E) Intro-
duction of a 24F orientable guiding 
catheter to the left atrium (LA). (F) 
Introduction of a steerable clip de-
livery catheter. (G–I) Advance of the 
device into the left ventricle (LV) and 
grasping of the mitral valve (yellow 
arrow) under the left ventricular out-
flow tract view and intercommisural 






symptoms (NYHA class II, III, or IV) while on optimal 
guideline-directed medical therapy for heart failure (stage 
D) [5]. Furthermore, we expect that the RESHAPE-HF2 
(NCT02444338) and MATTERHORN (NCT02371512) tri-
als might provide more concrete evidence and appropriate 
indications for the application of the MitraClip device for 
functional MR and the concept of disproportionate MR.
Step-by-step procedure
TEER is performed under general endotracheal anesthe-
sia. To access the left atrium, a trans-septal puncture is 
performed via the femoral vein. One or two Perclose Pro-
Glide devices (Abbott Vascular, Abbott Park, IL, USA) 
might be deployed in a pre-close fashion in the right com-
mon femoral vein followed by introduction of an 18F 
sheath to help hemostasis after the procedure. Trans-septal 
puncture is performed in a posterior and mid-to-superior 
location on the interatrial septum using transesophageal 
echocardiographic guidance after confirmation of an ade-
quate distance from the puncture location to the mitral 
annular plane (Fig. 1A–C). After trans-septal puncture, a 
24F orientable guiding catheter is percutaneously intro-
duced (Fig. 1D, E), and a steerable clip delivery catheter 
enables orientation of the clip (Fig. 1F). Throughout the 
entire procedure, transesophageal echocardiographic guid-
ance including real-time 3-dimensional images is import-
ant for the septal puncture, introduction of clip delivery 
system, positioning, and precision-targeting of the free 
edges of the opposing leaflets at the site of regurgitation. 
The device is then advanced into the left ventricle and 
while pulling back the catheter, the mitral valve leaflets are 
grasped (Fig. 1G–I).
Once optimal grasping has been undertaken, the clip is 
closed to create a double orifice (Fig. 2A, B). An echocar-
diographic assessment is performed for adequate leaflet in-
sertion, residual MR with color Doppler (Fig. 2C, D), and 
new trans-valvular gradients avoiding mitral stenosis prior 
to the final deployment. Direct measurements of the left 
atrial mean pressure and V wave provide complementary 
hemodynamic data to guide treatment decision-making 
(Fig. 2E, F). Multiple clips can be implanted to optimize 
imperfect results on a case-by-case basis if the gradients 
and anatomy allow. Hemodynamics usually remain very 
stable during the procedure and the recovery time is short.
Our initial experience and the results 
from major registries
At Severance Cardiovascular Hospital, between February 
2020 and January 2021, a total of 17 patients with moderate 
to severe or severe MR underwent TEER with the Mitra-
Clip NT system (Abbott Vascular), which is currently 
available in Korea. The patients’ median age was 81 years 
(interquartile range, 76–86 years) and 10 patients (59%) 
were women. The proportion of patients with NYHA III 
and IV functional status was 53% and 47%, respectively. 
The comorbidities were as follows: atrial fibrillation, 11 pa-
tients (65%); hypertension, 15 patients (88%); diabetes, 5 
patients (29%); and chronic kidney disease, 10 patients 
(59%). At the time of the procedure, 1 patient (6%) was in 
shock. The median EuroSCORE II was 5.0% (interquartile 
range, 2.3%–6.9%). The median Society for Thoracic Sur-
geons (STS) scores for mitral valve repair and mitral valve 
Fig. 2. Case example comparing before and after the procedure. 
(A) Before the procedure, A2 prolapse can be seen on 3-dimen-
sional transesophageal echocardiography (TEE) images. (B) Cre-
ation of a double orifice after clip closure. (C) Severe mitral regur-
gitation (MR) on the left ventricular outflow tract view of the TEE 
image before the procedure. (D) After the clip closure, MR was 
reduced to a trivial degree. (E) Before the procedure, the mean left 
atrial (LA) pressure was 35 mm Hg with a prominent V wave. (F) 
After the procedure, the mean LA pressure was 21 mm Hg with a 
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replacement were 6.8% (interquartile range, 4.0%–9.1%) 
and 9.0% (interquartile range, 8.0%–12.0%), respectively. 
The overwhelming majority of patients (88%) had STS 
scores ≥8% for mitral valve replacement. One patient had 
severe right ventricular dysfunction with severe tricuspid 
regurgitation. One patient had severe heart failure with 
chronic constrictive pericarditis.
Echocardiographic data are presented in Table 1. The 
median LVEF and end-diastolic diameter were 62% and 60 
mm, respectively. Before the procedure, 9 patients had 
grade 3+ MR and 8 patients had grade 4+ MR. Fig. 3A 
presents the procedural time (from the initiation of the 
trans-septal puncture to device deployment). It took a me-
dian of 129 minutes (interquartile range, 79–211 minutes; 
minimum, 70 minutes; maximum, 253 minutes). Twelve 
patients (71%) had 1 clip implanted and 5 patients (29%) 
required 2 clips; the average number of devices used was 
1.29. Post-implantation MR severity is presented in Table 1, 
and post-implantation MR grade ≤2 could be achieved in 
16 patients (94%) (Fig. 3B). The procedural complications 
and device-related adverse events were as follows: cardiac Table 1. Echocardiographic data (n=17)
Variable Value
Left ventricular ejection fraction (%) 62 (25–72)
End-diastolic diameter (mm) 60 (46–66)
End-systolic diameter (mm) 40 (31–49)
≥40 mm 9 (53)
Mitral regurgitation severity
   Grade 3 9 (53)
   Grade 4 8 (47)
Effective regurgitant orifice area (mm2) 0.47 (0.40–0.58)
Etiology of mitral regurgitation
   Degenerative 12 (71)
   Functional 3 (17)
   Degenerative and functional 2 (12)
Tricuspid regurgitation
   Grade 2 7 (41)
   Grade 3 1 (6)
   Grade 4 2 (12)
Right ventricular systolic pressure (mm Hg) 48 (23–62)
Post-implantation mitral regurgitation
   None/trivial 2 (12)
   Grade 1 5 (29)
   Grade 2 9 (53)
   Grade 3 1 (6)
   Grade 4 0
Post-implantation mitral regurgitation grade ≤2 16 (94)
Post-implantation mitral regurgitation grade ≤1 7 (41)
Values are presented as median (interquartile range) or number (%).



















ACCESS-EU [15] 567 74±10 22±18 - 23 77 91 3.4 11.8
TCVT [16] 628 74±10 20±17 - 28 72 95 2.9 15.3
TRAMI [17] 749 76 (71–81) 20 (12–31) 6 (4–11) 28 71 97 4.7 20.3
STS/ACC TVT [18] 2,952 82 (74–86) - 9 (6–14) 86 9 92 5.8 25.8
Asia-Pacific Registry [19] 142 71±12 17±15b) 7±8 53 47 94 5.6 -
Values are presented as number, mean±standard deviation, or median (interquartile range).
MR, mitral regurgitation; TCVT, Transcatheter Valve Treatment Sentinel Pilot Registry; TRAMI, transcatheter mitral valve interventions; STS, Society 
of Thoracic Surgeons; ACC TVT, American College of Cardiology Transcatheter Valve Therapy.
a)For mitral valve replacement. b)Logistic EuroSCORE; the others are EuroSCORE II.
Fig. 3. Our initial experiences with the MitraClip (Abbott Vascular, 
Abbott Park, IL, USA). (A) Total time (minutes) between the initi-
ation of trans-septal puncture to device deployment. (B) Severity 
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perforation (n=1), major bleeding requiring transfusion 
(n=1), mitral sub-valvular injury (n=1), transient ischemic 
attack (n=1), and air embolism (n=1). The 30-day mortality 
rate was 6% (1/17). In-hospital death occurred in 2 patients. 
One patient successfully underwent TEER before liver 
transplantation, but liver failure progressed while waiting 
for a cadaveric donor, and he died 3 months after the pro-
cedure. One patient had heart failure with progressive con-
strictive pericarditis combined with severe MR. Although 
the reduction of MR was successful after the procedure, 
the patient died because of progression of heart failure and 
liver failure.
The results from the other major registries, including the 
Asia-Pacific Registry, are presented in Table 2 [15-19]. The 
mean ages were in the 70s and 80s, and the EuroSCORE 
was around 20%. Acute procedural success was reported in 
91% to 97% of cases, and the 30-day mortality rate was 
2.9% to 5.8%.
Conclusion
The TEER procedure has been introduced to reduce MR, 
and its main advantages are that it is less invasive than sur-
gery, without any hemodynamic compromise or contrast 
use during the procedure. Though it started to be per-
formed in Korea in January 2020 (i.e., later than in many 
other countries), our initial experience was acceptable 
compared to other recent registry data. For primary MR, 
TEER can be performed for patients with a high or prohib-
itive surgical risk if the mitral valve anatomy is favorable 
for the TEER procedure. For chronic secondary MR, pa-
tients with severe MR with symptomatic heart failure on 
optimal guideline-directed medical therapy can be consid-
ered for TEER. Furthermore, it is important to select pa-
tients through a multidisciplinary approach with heart 
team discussion.
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